(Q38911797)

7 September 2017

title

Antibody-Mediated Blockade of Phosphatidylserine Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinomas Xenografts (English)

1 reference

7 September 2017

1 reference

Xiaoyun Cheng

1

1 reference

7 September 2017

Li Li

2

1 reference

7 September 2017

Philip E Thorpe

3

1 reference

7 September 2017

Adam C Yopp

4

1 reference

7 September 2017

Rolf A Brekken

5

1 reference

7 September 2017

Xianming Huang

6

1 reference

7 September 2017

language of work or name

1 reference

4 February 2016

1 reference

Annals of Surgical Oncology

7 September 2017

published in

1 reference

7 September 2017

volume

23

1 reference

7 September 2017

issue

Suppl 5

1 reference

7 September 2017

page(s)

583-591

1 reference

7 September 2017

cites work

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1245%2FS10434-016-5107-5

21 January 2018

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1245%2FS10434-016-5107-5

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-016-5107-5

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-016-5107-5

Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-016-5107-5

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-016-5107-5

Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-016-5107-5

Surface code--biophysical signals for apoptotic cell clearance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-016-5107-5

The immune functions of phosphatidylserine in membranes of dying cells and microvesicles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-016-5107-5

Innate apoptotic immunity: the calming touch of death

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-016-5107-5

Capitalizing on the immunogenicity of dying tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-016-5107-5

Combination of a monoclonal anti-phosphatidylserine antibody with gemcitabine strongly inhibits the growth and metastasis of orthotopic pancreatic tumors in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-016-5107-5

Antiphosphatidylserine antibody combined with irradiation damages tumor blood vessels and induces tumor immunity in a rat model of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-016-5107-5

A monoclonal antibody that binds anionic phospholipids on tumor blood vessels enhances the antitumor effect of docetaxel on human breast tumors in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-016-5107-5

Antitumor effects of a monoclonal antibody that binds anionic phospholipids on the surface of tumor blood vessels in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-016-5107-5

Phosphatidylserine-targeting antibody induces M1 macrophage polarization and promotes myeloid-derived suppressor cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-016-5107-5

Highly specific PET imaging of prostate tumors in mice with an iodine-124-labeled antibody fragment that targets phosphatidylserine

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-016-5107-5

Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-016-5107-5

Sorafenib: from literature to clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-016-5107-5

Plasma Protein β-2-Glycoprotein 1 Mediates Interaction between the Anti-tumor Monoclonal Antibody 3G4 and Anionic Phospholipids on Endothelial Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-016-5107-5

10.1245/S10434-016-5107-5

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

7 September 2017

1015149347

0 references

1 reference